Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics, Inc. (NTLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates - On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date - New lonvo-z patient perspectives and Phase 1/2 durability data to be includ

Intellia Therapeutics completed patient enrolment in the Phase III MAGNITUDE-2 study for nexiguran ziclumeran (nex-z), a CRISPR-based treatment for ATTRv-PN. The trial will assess safety and efficacy in 60 adults, with primary outcomes measured at day 29 and month 18. Intellia aims to halt or reverse disease progression with a single dose. The therapy is also being studied for ATTR-CM and has received regulatory designations from the FDA and European Commission.

Intellia Therapeutics (NASDAQ:NTLA) completed enrollment in the MAGNITUDE-2 phase 3 trial for nex-z, a CRISPR-based therapy for ATTRv-PN. The trial involves 60 patients and evaluates efficacy and safety over 18 months. Nex-z is also being tested in a separate phase 3 trial for ATTR-CM and has received Orphan Drug and RMAT designations. Intellia collaborates with Regeneron on its development.

Shares of gene editing therapy companies surged this week due to positive data from the ESGCT Congress and FDA draft guidance for personalized gene therapies. Prime Medicine (PRME) rose 29%, Beam Therapeutics (BEAM) 13%, Editas Medicine (EDIT) 11%, and Intellia Therapeutics (NTLA) 11%. The FDA's guidance aims to streamline approvals for individualized genome editing products. Analysts view the developments positively, anticipating continued momentum.

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.

Intellia Therapeutics (NTLA) appointed Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz brings extensive experience in rare disease therapies and will lead clinical development and regulatory affairs. The company is advancing its CRISPR gene editing pipeline, including Phase 3 trials for transthyretin amyloidosis.